Posts

Novo Nordisk to Cut 400 Jobs at Bloomington, Indiana Facility Amid Prior Ownership Layoffs

Novo Nordisk plans to lay off approximately 400 employees at its Bloomington, Indiana manufacturing facility, reducing the workforce from 1,800 to about 1,400, a 22% cut. 1 2 The layoffs are scheduled to take effect at the beginning of May 2026. 2 3 5 6 The Bloomington site was acquired by Novo Nordisk as part of its $11 billion purchase of Catalent in December 2024; Catalent had previously cut over 400 jobs there in December 2022. 1 2 Novo Nordisk describes the site as a critical part of its U.S. manufacturing network and will provide severance, outplacement assistance, and transition support to affected employees. 3 Bloomington Mayor Kerry Thomson stated the city will support impacted workers with job opportunities and resources. 2 3 Sources: 1. https://www.marketscreener.com/news/novo-nordisk-to-cut-400-jobs-at-catalent-facility-in-indiana-ce7e51dedf88f620 2. https://nationaltoday.com/us/in/bloomington-in/news/2026/03/31/novo-nordisk-to-cut-400-jobs-at-bloomington-indi...

Eli Lilly's Orforglipron Obesity Pill Gains FDA Approval, Challenging Novo Nordisk's Wegovy

No Recent NICE Cardio Approval for Wegovy

Dual-Action Molecule and Drug Combos Show Promise in Treating Multiple Cancers in Mice Models

FDA Approves Eli Lilly's Oral GLP-1 Pill Foundayo (Orforglipron) as Response to Novo Nordisk

Ambrosia Raises $100M Series B to Develop Next-Generation Small Molecule GLP-1s

Ambrosia Biosciences Raises $100M Series B for Oral GLP-1 Drug Development

Merck Partners with Infinimmune on $838 Million Antibody Discovery Deal

Novo Nordisk Launches Discounted Subscription Program for Wegovy

AstraZeneca's Efzimfotase Alfa Fails Phase 3 Trial in Adolescents and Adults with Hypophosphatasia

Public Perceptions and Economic Implications of MAHA in 2025 Research

Immunic Appoints Jon Congleton to Board of Directors

Astellas Announces Top Management Personnel Change: Nick Eshkenazi to Depart as CDTO